2016, Cilt 25, Sayı 0, Sayfa(lar) 194-196
Cessation of Ultrafiltration Therapy by Treating with Tolvaptan in a Patient with Hypervolemic Hyponatremic Heart Failure
DOI 10.5262/tndt.2016.48
Saim SAĞ1, Özlem KARAKAŞ2, Ahmet Bilgehan ŞAHİN3, Abdülmecit YILDIZ4, Bülent ÖZDEMİR1
1Uludağ University Faculty of Medicine, Department of Cardiology, Bursa, Turkey
2DışkapıYıldırım Beyazit Training and Research Hospital, Department of Internal Medicine, Ankara, Turkey
3Uludag University Faculty of Medicine, Department of Internal Medicine, Bursa, Turkey
4Uludağ University Faculty of Medicine, Department of Nephrology, Bursa, Turkey
Keywords: Heart failure, Hyponatremia, Tolvaptan, Ultrafiltration

Patients with heart failure (HF) often develop hyponatremia owing to the activation of many neurohormonal systems leading to decreased sodium levels. Treatment options for hyponatremia such as water restriction or the use of loop diuretics are present but patients do not always respond to treatment. Ultrafiltration (UF) is used in patients at an advanced stage of congestive HF and unresponsive to medical treatment. Tolvaptan, a vasopressin 2 receptor antagonist, has recently been used in hypervolemic hyponatremia in patients with heart failure. We report a 60-year-old man who had heart failure and hypervolemic hyponatremia that was resistant to medical treatment. Ultrafiltration was started but the treatment was stopped because of catheter infection. Tolvaptan was used for hyponatremia in this case and the patient did not need ultrafiltration again.

Türk Nefroloji Derneği'nin yayın organıdır.